80
Participants
Start Date
February 28, 2025
Primary Completion Date
October 31, 2026
Study Completion Date
April 30, 2027
BC001+Sintilimab+XELOX
patients will be given : BC001 8mg/kg, 12mg/kg or 16mg/kg intravenously once every three weeks; Sintilimab 3mg/kg(body weight\<60kg)or 200mg(body weight≥60kg)intravenously once every three weeks; Oxaliplatin 130mg/m2 intravenously once every three weeks; Capecitabine 1000mg/m2 orally once daily in the first two weeks of each three-week treatment cycle.
RECRUITING
Beijing Cancer Hospital, Beijing
Peking University Cancer Hospital & Institute
OTHER
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
INDUSTRY